$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Refuses Deramiocel Over Trial Data Integrity Violations

The agency's complete response letter for Capricor Therapeutics' cell therapy rests on inspection findings in Study HOPE-3. The FDA says those violations can't be fixed after the fact.

TML Health DeskNov 22, 4:54 AM ET · 1 min read
FDA headquarters at White Oak, Maryland (file photo). Photo: U.S. Food and Drug Administration / public domain, via Wikimedia Commons.
Summary

The flaw was in the data.

Tap a passage. React to the part that matters.

The FDA refused Capricor's deramiocel application on November 20, citing serious data integrity violations in the trial behind it that can't be repaired now.

Deramiocel is a cell therapy proposed for the heart damage caused by Duchenne muscular dystrophy. Capricor Therapeutics filed a biologics license application asking the FDA to approve it. On November 20 the agency answered with a complete response letter, the formal refusal that stops an approval until the problems in the file are resolved.

The problem here is not the size of the benefit or the shape of the trial. An FDA inspection of Study HOPE-3, run under the agency's bioresearch monitoring program, found serious data integrity violations. The agency says violations of this kind can't be fixed after the fact, because the record a trial produces can't be rebuilt once the trial has run.

Capricor tried to answer inside the review. The company filed a major amendment adding 24-month open-label extension data from HOPE-3-OLE and proposing a different indication. The FDA weighed the amendment and found the file still short of the evidentiary standard. A Cellular, Tissue, and Gene Therapy Advisory Committee had already met on the application on July 29, 2026.

What this refusal doesn't say matters too. The statement doesn't report that the therapy harmed patients, and it doesn't close the door on the drug itself. It closes the door on this dataset. A therapy for Duchenne heart disease will now stand or fall on data the agency can trust, and producing that data means new trial work, not new arguments.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.